Using the 21 ‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial

ConclusionsUsing the RS to guide NST is feasible. These results suggest that for patients with RS < 25 NHT is a potentially effective strategy.

Source: Journal of Surgical Oncology - April 13, 2017 Category: Cancer & Oncology Authors: Harry D. Bear, Wen Wan, Andr é Robidoux, Peter Rubin, Steven Limentani, Richard L. White, James Granfortuna, Judith O. Hopkins, Dwight Oldham, Angel Rodriguez, Amy P. Sing Tags: RESEARCH ARTICLE Source Type: research